July - September 2021, Volume 17, Issue 3

Capatina C, Poiana C

Dopamine Agonists in the Management of Non-Functioning Pituitary Adenomas

Acta Endo (Buc) 2021, 17 (3): 377-382
doi: 10.4183/aeb.2021.377

Non-functioning pituitary tumors (NFPA) are usually large at the time of diagnosis and present with symptoms caused by compression on the neighbouring structures. Transsphenoidal resection of the tumor is the firstline treatment but in many cases complete tumor resection cannot be attained. Close follow-up with repeated hormonal assessment and pituitary imaging is recommended after surgery. During follow-up of the tumor remnant sometimes radiotherapy is used to stop or prevent tumor progression. Medical treatment with dopamine agonists (DA) is the mainstay in the management of prolactinomas. For NFPA several small series or case reports suggested beneficial effects with tumor shrinkage in some cases. The aim of the current paper is to summarize the available evidence related to the potential efficacy of DA medical treatment in NFPA while underlining that in the absence of randomized, placebocontrolled studies, no final conclusion on the efficacy of these drugs in the treatment of NFPA can be drawn.

Keywords: dopamine agonists, non-functioning, pituitary, adenomas.

Correspondence: Cristina Capatina MD, “Carol Davila” University of Medicine and Pharmacy, Dept. of Endocrinology, 34-36 Aviatorilor blvd., Bucharest, 011863, Romania, E-mail: cristina.capatina@yahoo.com